CymaBay flash­es pos­i­tive re­sults from the tri­al they have to re­launch

Two weeks af­ter the FDA lift­ed its clin­i­cal hold on their lead drug, CymaBay said it showed pos­i­tive re­sults in an abort­ed Phase III tri­al.

The drug, a small mol­e­cule known as se­ladel­par, had been in de­vel­op­ment for three dif­fer­ent liv­er con­di­tions be­fore an in­de­pen­dent re­view of a NASH study last year showed that it might ac­tu­al­ly be dam­ag­ing pa­tient’s liv­er cells. The FDA slapped a clin­i­cal hold across all three tri­als, on­ly lift­ing it last month when an FDA re­view de­ter­mined that the drug hadn’t caused liv­er dam­age.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER